Exablate Neuro

20 Pages Posted: 30 May 2017

See all articles by Robert E. Spekman

Robert E. Spekman

University of Virginia - Darden School of Business

Matthew Thames

affiliation not provided to SSRN

Abstract

This case examines InSightec, a company that had pioneered a therapeutic medical technology known as magnetic-resonance-guided focused ultrasound surgery with a product line named ExAblate. Further developing the technology to include brain treatments in a product called ExAblate Neuro, InSightec had the proprietary ability to safely penetrate the skull en route to a targeted lesion. Among other ailments, essential tremor (ET) appeared to be effectively treated in this manner. With FDA approval of ExAblate Neuro expected within two to three years, InSightec's VP of sales and marketing in the Americas was now tasked with devising a go-to-market strategy for the launch of this innovative new medical device in the complex and evolving U.S. health care market.

Excerpt

UVA-M-0888

Rev. Dec. 8, 2015

ExAblate Neuro

Introduction

Judy Davis, VP of sales and marketing in the Americas for InSightec, closed out of the video conference with Jeffrey Elias, principal investigator of InSightec's Phase 3 clinical trial for its new ExAblate Neuro device. The news had been good; recruitment had officially closed, and the pivotal study was running on schedule. Although results were not yet released, Davis and the rest of InSightec's management were confident that they would be favorable, and initial submissions to the U.S. Food and Drug Administration (FDA) would be feasible by year-end 2016. Everything was going according to plan, but Davis was painfully aware that there was not much of a business plan left to execute.

InSightec was a privately held company headquartered in Israel that had pioneered a therapeutic medical technology known as magnetic-resonance-guided focused ultrasound surgery (MRgFUS). Focused ultrasound referred to the precise concentration of sound waves to act on a particular target segment of the human body. The guidance of magnetic resonance imaging (MRI) technology allowed for noninvasive targeted destruction of diseased tissue throughout the body, otherwise known as therapeutic ablation. InSightec currently provided this technology, for a very limited set of indications, with a product line named ExAblate.

. . .

Keywords: marketing strategy, medical devices, health care, marketing planning process, B to B marketing, healthcare innovation

Suggested Citation

Spekman, Robert E. and Thames, Matthew, Exablate Neuro. Darden Case No. UVA-OM-1537, Available at SSRN: https://ssrn.com/abstract=2974740

Robert E. Spekman (Contact Author)

University of Virginia - Darden School of Business ( email )

P.O. Box 6550
Charlottesville, VA 22906-6550
United States
434-924-4860 (Phone)

HOME PAGE: http://www.darden.virginia.edu/faculty/spekman.htm

Matthew Thames

affiliation not provided to SSRN

No Address Available

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
0
Abstract Views
427
PlumX Metrics